Rare diseases
Investigational molecules
Locations
215 Church Street, 06510-1803, United States
Biohaven Pharmaceuticals Inc. is active in clinical research for Obsessive Compulsive Disorder, with studies centered on patients who have not responded adequately to standard SSRI and related antidepressant treatments.
The sponsor’s psychiatric research includes evaluation of symptom improvement and longer-term safety and tolerability in individuals living with persistent compulsive and intrusive symptoms.
Biohaven Pharmaceuticals Inc. runs clinical trials in conditions such as Anxiety disorder, Spinal muscular atrophy, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to Current Treatment
ItalyLong-Term Safety Study of Troriluzole for Patients with Obsessive Compulsive Disorder Not Responding to SSRI, Clomipramine, Venlafaxine, or Desvenlafaxine
ItalyStudy of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
